Table 3.
Disease-specific survival byCox regression analysesbetween the subgroups of various clincopathological parameters
| Parameters | No | No of events | HR (95% CIa) | p-valueb |
|---|---|---|---|---|
| Age (years) |
|
|
1.695 (0.743-3.875) |
0.211 |
| <50 |
24 |
8 |
|
|
| ≥ 50 |
39 |
19 |
|
|
| Gender |
|
|
0.596 (0.225-1.575) |
0.297 |
| Male |
47 |
22 |
|
|
| Female |
16 |
5 |
|
|
| Histology |
|
|
0.930 (0.431-.006) |
0.854 |
| WHO type II |
37 |
16 |
|
|
| WHO type III |
26 |
11 |
|
|
| Primary tumor (T) |
|
|
5.091 (2.350-11.030) |
<0.001 |
| T1-T2 |
44 |
12 |
|
|
| T3-T4 |
19 |
15 |
|
|
| Nodal status (N) |
|
|
2.780 (1.302-5.934) |
0.009 |
| N0-N1 |
41 |
13 |
|
|
| N2-N3 |
22 |
14 |
|
|
| AJCC staging |
|
|
4.464 (1.879-10.607) |
0.001 |
| Stage I-II |
31 |
7 |
|
|
| Stage III-IV |
32 |
20 |
|
|
| FLJ10540 |
|
|
4.741 (2.177-10.326) |
<0.001 |
| Low expression |
42 |
11 |
|
|
| High-expression |
21 |
16 |
|
|
| Osteopontin |
|
|
5.012 (2.315-10.850) |
<0.001 |
| Low expression |
47 |
14 |
|
|
| High-expression | 16 | 13 |
Abbreviations: HR Hazard Ratio, WHO World Healthy Organization; AJCC American Joint Committee on Cancer.
a 95% Wald Confidence Limits.
b Associations determined by Cox regression analyses. Statistically significant (p < 0.05).